Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus

Launched by AIN SHAMS UNIVERSITY · May 12, 2015

Keywords

ClinConnect Summary

Lichen planus is a chronic, immunological, mucocutaneous disease, characterized by periods of remission and relapse1. Oral lichen planus (OLP) is one of the most common mucocutaneous diseases manifesting in the oral cavity, and the oral mucosa may be the only site of involvement 2, with variable incidence between 0.5% and 4% 3. Three major clinical forms of OLP (reticular, erosive/ ulcerative, and erythematous/atrophic) have been recognized, which could alternate and overlap in a dynamic state as disease progresses. Ulceration is the most severe form that it interferes with eating, speech, ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • clinically and histologically confirmed painful Erosive or Atrophic OLP
• • free from any systemic diseases using medical questionnaire guided by Cornell Medical Index
• Exclusion Criteria:
• • history of drug induced lichenoid lesions
• • potential treatment of OLP for less than 2 weeks by topical and 4 weeks systemic therapy before study start
• • pregnant or breast-feeding women,
• • smoking and
• • known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation
• • loss of paliability or flexibility in the tissues involved by the oral lesions or histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites.